YolTech's In Vivo Base Editing Therapy Goes Global in Over $2 Billion Deal, Licensee Serapha Bio to Merge and List on Nasdaq via SPAC | Unity Ventures Portfolio
"Driven by a dual-engine model of 'technology platform + clinical data,' forging a unique path to value realization"
Recently, gene-editing upstart Serapha Bio signed a merger agreement with Nasdaq-listed Boundless Bio and simultaneously completed a $230 million financing round co-led by RA Capital Management and RTW Investments. The core asset of this NewCo, SERP-01, comes from Unity Ventures portfolio company YolTech Therapeutics.
This is not YolTech's first appearance on the BD deal stage. From its over 1 billion RMB domestic licensing deal with Salubris in 2024 to its global BD through the Serapha NewCo model in 2026, this company founded in 2021 is carving out a distinctive value-realization path driven by its "technology platform + clinical data" dual engine.
First BD Deal Closed: Partnership with Salubris Tests Domestic Commercialization
In August 2024, YolTech reached a licensing agreement with Shenzhen Salubris, granting Salubris exclusive development and commercialization rights for YOLT-101 in mainland China. The total deal value reached 1.035 billion RMB, including up to 205 million RMB in upfront and R&D milestone payments, up to 830 million RMB in sales milestone payments, plus tiered royalties.
YOLT-101 is an in vivo base-editing drug targeting PCSK9 for the treatment of familial hypercholesterolemia. The drug uses YolTech's proprietary base editor YolBE® and novel lipid nanoparticle YOL-LNPs® delivery vehicle, achieving substantial and durable LDL-C reduction through a single administration.
This deal carried dual significance for YolTech: first, securing R&D funding through the upfront payment; second, accelerating product launch in the China market by leveraging Salubris's capabilities in cardiovascular clinical development and commercialization. This was one of the few large-scale licensing deals in China's in vivo gene editing space, and it provided initial external validation of YolTech's technology platform.
BD Advancement: Serapha NewCo Leverages Global Value
If the Salubris partnership was a "domestic test run," then the June 2026 transaction with Serapha Bio represented a comprehensive upgrade of YolTech's BD strategy.
In June 2026, Serapha Bio obtained global exclusive rights to SERP-01 outside Greater China from YolTech. In exchange, YolTech received an upfront payment, a minority equity stake in Serapha, and became eligible for over $2 billion in regulatory and commercial milestone payments, plus tiered royalties on net sales.
Simultaneously, Serapha Bio signed an all-stock merger agreement with Nasdaq-listed Boundless Bio. The combined company will operate under the name Serapha Bio, Inc., and is expected to trade on Nasdaq under the ticker "AATD," with $230 million in concurrent private financing commitments.
The core asset SERP-01 is the same drug as YolTech's self-developed YOLT-202. This is an in vivo base-editing therapy for alpha-1 antitrypsin deficiency (AATD), based on YolTech's next-generation adenine base editor YolBE, which enables precise gene repair at the SERPINA1 PiZ site, correcting the high-risk PiZ mutation to normal PiM. While achieving precise targeted editing, this therapy almost completely avoids bystander editing of surrounding bases, offering a "one-shot cure" new pathway for AATD treatment.
Prior to this, YOLT-202 had received FDA Orphan Drug Designation and, in March 2026, obtained FDA IND approval enabling direct initiation of Phase II/III clinical studies. In China, YolTech has already launched an investigator-initiated trial at Shanghai Renji Hospital.
Key clinical data showed rapid, dose-dependent rises in functional AAT levels in subjects, with AAT levels reaching the normal range in some high-dose subjects. These results indicate YOLT-202 has the potential to become a best-in-class global treatment requiring only a single administration.
Multi-Pipeline Synergistic Validation: Dual Realization of Platform Value and Clinical Execution
The reason YolTech's BD deals could leap from the 1 billion RMB magnitude in 2024 to the $2 billion magnitude in 2026 is inseparable from its layout of multiple pipelines advancing simultaneously with cross-validating data across multiple indications.
As of early 2026, the company had 7 pipelines in clinical stages, making it the company with the most in vivo gene editing pipelines in clinical stages globally.
But the technology platform is only the "entry ticket" for BD. What truly drives large transactions is the positive clinical data demonstrated by YOLT-202 in IIT, and the platform reliability simultaneously validated by multiple pipelines including YOLT-101, YOLT-201, and YOLT-203. The leap from "platform value" to "data value" is the core driver behind the magnitude jump in YolTech's two BD deals.
YolTech's pipeline covers ATTR amyloidosis, primary hyperoxaluria, hypercholesterolemia, AATD, and other indications. Among these, YOLT-201 is China's first LNP-based in vivo gene editing drug to enter registrational clinical trials; YOLT-203 has received FDA approval to enter confirmatory clinical trials. The strategy of multiple pipelines in parallel and multiple indication layouts allows YolTech to present different "flagship products" in different BD deals, offering differentiated licensing assets to different partners.
Companies that master platform technologies such as novel editors or efficient delivery systems and have clinical progress in major disease areas are becoming core targets of global BD transactions. For Chinese biotech companies, BD is even more of a strategic channel to enter the global innovation network and maximize technology value.
Source: BioMap BioPharma
Momenta IPO | A Decade of Partnership, Physical AI's First Public Listing
AI Debug Night | Unity Ventures AI Wonder Night WAIC Special Edition
